The Use of ESAs in Patients With Breast Cancer
Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the use of erythropoiesis stimulating agents (ESAs) in patients with breast cancer.
Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the use of erythropoiesis stimulating agents (ESAs) in patients with breast cancer.
There has been a lot of controversy in this space. At the 2013 Breast Cancer Symposium, Leyland-Jones presented the latest meta-analysis, which looked at 9 current studies in breast cancer randomizing ESAs versus no ESAs.
Clinical Pearls
The meta-analysis looked at 5 endpoints and found that mortality increased 20% when using ESAs. In studies with target hemoglobin levels at or less than 12 grams per deciliter (g/dL), the hazard ratio was reduced to 1.03. Leyland-Jones says that when using ESAs, the target hemoglobin levels must be reduced to 12 g/dL to reduce the mortality rate.
- There has been a lot of controversy over the use of ESAs in breast cancer
- The latest meta-analysis looked at 9 current studies which randomized ESAs vs no ESAs
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
